# Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

Source: https://onco.cc/trials/nct06475352/  
OnCo record `nct06475352` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by UNICANCER, now recruiting.

## Summary

Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme is a phase 2, interventional study registered as NCT06475352 by UNICANCER, with a registry enrolment figure of 400 participants, started 2025-01-20 and due to reach its primary completion in 2027-04. Interventions recorded: FOLFOX regimen; CAPOX regimen. Conditions listed: Digestive Cancer; Colorectal Cancer. Primary outcome: Proportion of fluoropyrimidine-induced grade ≥ 3 haematological and gastrointestinal toxicity after 2 cycles. Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: FUDOSE
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06475352
- Phase: 2
- Setting: Dihydropyrimidine Dehydrogenase (DPD) Phenotype-guided Dose Individualization of Fluoropyrimidine-based Chemotherapy in DPD Deficient Patients With Gastrointestinal Cancers
- Sponsor: UNICANCER
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT06475352: https://clinicaltrials.gov/study/NCT06475352

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- companies: [UNICANCER](https://onco.cc/companies/unicancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06475352.json